Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nope, .0001 restistance thinned out already. Just needs some moderate volume on the bid side.
Like ringing a gong.
It appears the same 400 million sell order has been entered and pulled few times in recent trading days. Somebody posted here that it was his 400 million but suggested he really didn't intend to sell. I would suggest it's uncertainty, thinking he should sell when he sees little buying interest then changing his mind when he sees some volume buying. There's always some of that. We're close to taking on an .0002 ask.
Tastes like chicken.
Not diddly. More than that traded already today.
That'll take out .0002s, maybe some .0003s IMO.
Nope, not anything close to that. Ask about to go. It's gettiing obvious now.
Down from 200 and 400 million increments.
Might be all they have.
It's in the prospectus as amended. Doesn't have to sell but can hold untill QX or Nasdaq uplisting, but they can sell at .00014 any time before.
Holding long IMO. Nothing to lose. They have a standing, binding buyout offer in hand.
We really haven't had much volume for two or three months.
Hmmm, people who believe ridiculous posts like yours maybe.
Looks like someone answered your question with cash.
2023 revenue over $20 million at a "run rate of $25-30 million" py and climbing with earnings of $2-3 miilion. Debt reduction rate through Q3 of $1 million per quarter. $1.5 million py in interest savings from debt restructuring so far on top of the interest savings from debt reduction. News comining anytime on more "restructuring of debt and other securities."
Price targets set at a forward P/E of 20-25 get it there. The OS doesn't matter. It's about the EPS and P/E now.
Everybody who has read through the corporate equity info in the 10-Qs knows some lesser (massively diluted) preferred share series expired over a year ago. The 2023 increase in the OS before November was those conversions. The preferred shares were retired, and no new preferred shares were issued in 2023. Those shareholders lost their preferred equity postition which only really matters in a bankruptcy or liquidation. GeekOfSkidRow is the stupid one.
I went a little digitty too this week watching the ticker. I really thought the last update was enough to give the street the confidence to take out the ask. I still think it was enough and the street just doesn't realize it. OTC volume thin all week. No explaining when and why trading decisions get made sometimes. RNVA is definately close to taking out the .0001 ask and taking on the .0002s though.
Thanks for the links. I'll do my reading this weekend. Myrtle may be eligible for some of this. Even if not directly, it's all money in the market (system) that brings patients to the admissions desk. Good eye.
You said exactly what I said. The conditions resulted in RSs and overselling. Proof in hand, growth in earnings/revenue, the rate of debt reduction, and a current P/E under 2. RNVA issued no new equity in 2023, not to pay the bills, not to pay debt, not for anything. I don't care what you believe, even if you really believe it. I care about the truth. I do my own DD. I form my opinions and make my decisions based on facts, not your beliefs, not even my own beliefs. But thanks for playing.
According to the CEO, news coming on more debt reduction and or "restructuring debt and other securites"
In the $3 million in debt reduced in the first three quarters of '23. Where have you been?
A lot of good will behind RNVA.
RNVA is a good investment you can feel good about.
Nice of him to take time out from feeding the poor and healing the sick just to save us. I'm eternally grateful.
Turtles, in 30 years of dabbling with OTC stocks, occassionally some serious dabbling, I have never seen a better value investment in the 000s than RNVA. I'm being 100% honest when I say that, no pumping, not hyperbole. The fundementals are great, reducing debt at a clip of $1 million per quarter. The pace of balance sheet improvement and the extremely low P/E have proven that RNVA was artificially diluted by oversold conditions. There are plenty of pigs in OTC, but not RNVA. If you want to see bloated, look on the big boards.
Yep, run rate of $25-30 million py and climbing from existing services. Then comes $30-40 million in CAH reimbursable services at Jamestown (proven CAH model replicated). Future replications? RNVA a MA target?
As per recent filings and updates, the CEO has cleared the way for the street to take out the ask and trade it up, no insider selling in the way. News coming on more debt reduction and/or more restructuring of debt "and other securities." At least $2 million earnings on $20 million revenue (with certainty in the cost of revenue ratio from CAH reimbursements. P/E below 2. Forward P/E as low as 1. That's the deal.
OTC volume is pathetic. The big banks and their commercial investment cronies herd all the QE money into the big boards, including Nasdag listed companies burning through working capital and diluting all the way. Small investors don't get the memo when they declare a correction or start channeling some money back into OTC exchanges. Small companies with greater value than many on the Nasdaq are investment starved even as the big boards grow more speculative than the OTC. Something has to give.
October 2022 appeared to be a gang playing the bounce while others cut their losses. I never looked into it very deeply. Didn't think much of it at the time. 000s had seen volume like that earlier that year and several times the year before. RNVA volume is due to pick up quite a bit.
You would think it would be enough that RNVA has already reported $2.9 million in debt reduction plus the debt restructuring, together yielding over $2 million in interest savings.
News coming on more debt reduction and/or "restructuring of debt and other securities." The CEO telegraphed that one on 10/25/23.
All certainly plausable. Then again, the company is good if the price goes up tomorrow too. There is a win win in that amendment.
RNVA was oversold in 2022. It should not have been sold down into the 000s. If not for the bear OTC market, it would have only tested the high 000s at worst. The oversold condition artificially diluted the stock. The current P/E of 1.74 has proven that out. With revenues over $20 million py and climbing and CAH reimbursments above the fixed cost (certainty in cost of revenue ratio and earnings), RNVA is undervalued by any measure. The price will rebound, no excuses, no fixes please and thank you.
In 2022, new SEC insider trading rules went into effect requiring an insider trading plan to be filed at least 90 days before the trading takes place by any shareholder of 15% or more of any equity class (meaning 15% of common shares or of a class of preferred shares).
On 12/30/22, RNVA filed an insider trading plan for the sell of just under 10 billion common shares to be converted from preferred shares. The plan went into effect on 05/12/23. Three days later, the prospectus was filed revealing that the seller was the holder of Series B preferred shares and requiring that shareholder to sell at a price no higher than .00014 after conversions at .00009. RNVA was to receive the proceeds.
On 01/11/24, the prospectus/insider trading was amended so the Series B preferred shareholder is no longer required to sell and RNVA no longer plans to receive the proceeds (necessarily). The Series B preferred shareholder can hold until RNVA is uplisted to QX or Nasdaq with a standing offer from the company at .00014 just in case.
The increase in the OS in 2023 was lesser preferred shareholders with diluted equity too small to require an insider trading plan. Some bulls on this board own more common shares than any of those do now. Not dilution, the OS increased but the equity in preferred shares went away.
Now, add the company's revelation that the OS has not increased since sometime before early November, and the CEO has issued an engraved invitation for street investors to take out the ask for good, no surprises, no significant insider sellers in the way. Buybacks of corportate equity are not subject to insider trading reporting requirements.
Did that help?
I'm in it because of the certainty in the CAH cost of revenue ratios, the year old insider trading reporting requirements that few OTC traders seem to know or understand, and six earnings reports in a row showing a company turnaround. I own no other OTC stock and haven't seen one for a good while that I would touch other than RNVA. To each his own.
RNVA gets paid for the fixed costs. Humana does not, except at CAHs it owns, if any.
https://www.forbes.com/sites/gebai/2024/01/21/rural-urban-healthcare-access-gap-its-all-about-the-fixed-costs/?sh=e764b046288f
RNVA is not for low information, momentum chasing daytraders.
You bet. $30-40 million in CAH reimbursable revenue at Jamestown.
They are advertising to hire nurses for Big South Fork and Jamestown, probably hiring to transfer when ready or to assign to either as needed.